[1]
|
B. Munos, “Lessons from 60 Years of Pharmaceutical Innovation,” Nature Reviews Drug Discovery, Vol. 8, No. 12, 2009, pp. 959-968. http://dx.doi.org/10.1038/nrd2961
|
[2]
|
P. Imming, C. Sinning and A. Meyer, “Drugs, Their Targets and the Nature and Number of Drug Targets,” Nature Reviews Drug Discovery, Vol. 5, No. 10, 2006, pp. 821-834. http://dx.doi.org/10.1038/nrd2132
|
[3]
|
S. Paul, “Steven Paul,” Nature Reviews Drug Discovery, Vol. 8, No. 1, 2009, p. 14. http://dx.doi.org/10.1038/nrd2800
|
[4]
|
M. V. Chao, R. Rajagopal and F. S. Lee, “Neurotrophin Signalling in Health and Disease,” Clinical Science (London), Vol. 110, 2006, pp. 167-173. http://dx.doi.org/10.1042/CS20050163
|
[5]
|
X. L. He and K. C. Garcia, “Structure of Nerve Growth Factor Complexed with the Shared Neurotrophin Receptor p75,” Science, Vo. 304, No. 5672, 2004, pp. 870-875. http://dx.doi.org/10.1126/science.1095190
|
[6]
|
T. Wehrman, X. He, B. Raab, A. Dukipatti, H. Blau and K. C. Garcia, “Structural and Mechanistic Insights into Nerve Growth Factor Interactions with the TrkA and p75 Receptors,” Neuron, Vol. 53, No. 1, 2007, pp. 25-38. http://dx.doi.org/10.1016/j.neuron.2006.09.034
|
[7]
|
D. W. Sah, M. H. Ossipo and F. Porreca, “Neurotrophic Factors as Novel Therapeutics for Neuropathic Pain,” Nature Reviews Drug Discovery, Vol. 2, No. 6, 2003, pp. 460-472. http://dx.doi.org/10.1038/nrd1107
|
[8]
|
A. Dray, “Neuropathic Pain: Emerging Treatments,” British Journal of Anaesthesia, Vol. 101, No. 1, 2008, pp. 48-58. http://dx.doi.org/10.1093/bja/aen107
|
[9]
|
J. B. Owolabi, G. Rizkalla, A. Tehim, G. M. Ross, R. J. Riopelle, R. Kamboj, M. Ossipov, D. Bian, S. Wegert, F. Porreca and D. K. Lee, “Characterization of Antiallodynic Actions of ALE-0540, a Novel Nerve Growth Factor Receptor Antagonist, in the Rat,” Journal of Pharmacology and Experimental Therapeutics, Vol. 289, 1999, pp. 1271-1276.
|
[10]
|
O. Niederhauser, M. Mangold, R. Schubenel, E. A. Kusznir, D. Schmidt and C. Hertel, “NGF Ligand Alters NGF Signaling via p75(NTR) and trkA,” Journal of Neuroscience Research, Vol. 61, No. 3, 2000, pp. 263-272. http://dx.doi.org/10.1002/1097-4547(20000801)61:3<263::AID-JNR4>3.0.CO;2-M
|
[11]
|
K. Spiegel, D. Agrafiotis, B. Caprathe, R. E. Davis, M. R. Dickerson, J. H. Fergus, T. W. Hepburn, J. S. Marks, M. Van Dorf, D. M. Wieland, et al., “PD 90780, a Non Peptide Inhibitor of Nerve Growth Factor’s Binding to the P75 NGF Receptor,” Biochemical and Biophysical Research Communications, Vol. 217, No. 2, 1995, pp. 488-494. http://dx.doi.org/10.1006/bbrc.1995.2802
|
[12]
|
J. K. Eibl, S. A. Chapelsky and G. M. Ross, “Multipotent Neurotrophin Antagonist Targets Brain-Derived Neurotrophic Factor and Nerve Growth Factor,” Journal of Pharmacology and Experimental Therapeutics, Vol. 332, No. 2, 2010, pp. 446-454. http://dx.doi.org/10.1124/jpet.109.159079
|
[13]
|
N. Q. McDonald, R. Lapatto, J. Murray-Rust, J. Gunning, A Wlodawer and T. L. Blundell, “New Protein Fold Revealed by a 2.3-A Resolution Crystal Structure of Nerve Growth Factor,” Nature, Vol. 354, No. 6352, 1991, pp. 411-414. http://dx.doi.org/10.1038/354411a0
|
[14]
|
T. A. Halgren, “Maximally Diagonal Force Constants and Dependent Angle Bending Coordinates II. Implecations for the Design of Emperical Forcefields,” Journal of the American Chemical Society, Vol. 112, No. 12, 1990, pp. 4710-4723. http://dx.doi.org/10.1021/ja00168a015
|
[15]
|
A. N. Jain, “Scoring Noncovalent Protein-Ligand Interactions: A Continuous Differentiable Function Tuned to Compute Binding Affinities,” Journal of Computer-Aided Molecular Design, Vol. 10, No. 5, 1996, pp. 427-440. http://dx.doi.org/10.1007/BF00124474
|
[16]
|
M. M. Berg, D. W. Sternberg, L. F. Parada and M. V. Chao, “K-252a Inhibits Nerve Growth Factor-Induced trk Proto-Oncogene Tyrosine Phosphorylation and Kinase Activity,” The Journal of Biological Chemistry, Vol. 267, 1992, pp. 13-16.
|
[17]
|
B. Knusel and F. Hefti, “K-252 Compounds: Modulators of Neurotrophin Signal Transduction,” Journal of Neurochemistry, Vol. 59, No. 6, 1992, pp. 1987-1996. http://dx.doi.org/10.1111/j.1471-4159.1992.tb10085.x
|
[18]
|
B. Lippa, J. Morris, M. Corbett, T. A. Kwan, M. C. Noe, S. L. Snow, T. G. Gant, M. Mangiaracina, H. A. Coffey, B. Foster, E. A. Knauth and M. D. Wessel, “Discovery of Novel Isothiazole Inhibitors of the TrkA Kinase: Structure-Activity Relationship, Computer Modeling, Optimization, and Identification of Highly Potent Antagonists,” Bioorganic & Medicinal Chemistry Letters, Vol. 16, No. 13, 2006, pp. 3444-3448. http://dx.doi.org/10.1016/j.bmcl.2006.04.003
|
[19]
|
J. J. Watson, S. J. Allen and D. Dawbarn, “Targeting Nerve Growth Factor in Pain: What Is the Therapeutic Potential?” BioDrugs, Vol. 22, No. 6, 2008, pp. 349-359. http://dx.doi.org/10.2165/0063030-200822060-00002
|
[20]
|
S. M. Massa, T. Yang, Y. Xie, J. Shi, M. Bilgen, J. N. Joyce, D. Nehama, J. Rajadas and F. M. Longo, “Small Molecule BDNF Mimetics Activate TrkB Signaling and Prevent Neuronal Degeneration in Rodents,” Journal of Clinical Investigation, Vol. 120, No. 5, pp. 1774-1785. http://dx.doi.org/10.1172/JCI41356
|
[21]
|
F. M. Longo and S. M. Massa, “Small Molecule Modulation of p75 Neurotrophin Receptor Functions,” CNS & Neurological Disorders—Drug Targets, Vol. 7, No. 7, 2008, pp. 63-70. http://dx.doi.org/10.2174/187152708783885093
|
[22]
|
F. Brahimi, A. Malakhov, H. B. Lee, M. Pattarawarapan, L. Ivanisevic, K. Burgess and H. U. Saragovi, “A Peptidomimetic of NT-3 Acts as a TrkC Antagonist,” Peptides, Vol. 30, No. 10, 2009, pp. 1833-1839. http://dx.doi.org/10.1016/j.peptides.2009.07.015
|
[23]
|
D. Chen, F. Brahimi, Y. Angell, Y. C. Li, J. Moscowicz, H. U. Saragovi and K. Burgess, “Bivalent Peptidomimetic Ligands of TrkC Are Biased Agonists and Selectively Induce Neuritogenesis or Potentiate Neurotrophin-3 Trophic Signals,” ACS Chemical Biology, Vol. 4, No. 9, 2009, pp. 769-781. http://dx.doi.org/10.1021/cb9001415
|
[24]
|
S. Covaceuszach, A. Cassetta, P. V. Konarev, S. Gonfloni, R. Rudolph, D. I. Svergun, D. Lamba and A. Cattaneo, “Dissecting NGF Interactions with TrkA and p75 Receptors by Structural and Functional Studies of an Anti-NGF Neutralizing Antibody,” Journal of Molecular Biology, Vol. 381, No. 4, 2008, pp. 881-896. http://dx.doi.org/10.1016/j.jmb.2008.06.008
|
[25]
|
M. Vilar, I. Charalampopoulos, R. S. Kenchappa, A. Simi, E. Karaca, A. Reversi, S. Choi, M. Bothwell, I. Mingarro, W. J. Friedman, G. Schiavo, P. I. Bastiaens, P. J. Verveer, B. D. Carter and C. F. Ibanez, “Activation of the p75 Neurotrophin Receptor through Conformational Rearrangement of Disulphide-Linked Receptor Dimers,” Neuron, Vol. 62, No. 1, 2009, pp. 72-83. http://dx.doi.org/10.1016/j.neuron.2009.02.020
|
[26]
|
Y. Gong, P. Cao, H. J. Yu and T. Jiang, “Crystal Structure of the Neurotrophin-3 and p75NTR Symmetrical Complex,” Nature, Vol. 454, 2008, pp. 789-793.
|
[27]
|
D. Feng, T. Kim, E. Ozkan, M. Light, R. Torkin, K. K. Teng, B. L. Hempstead and K. C. Garcia, “Molecular and Structural Insight into proNGF Engagement of p75NTR and Sortilin,” Journal of Molecular Biology, Vol. 396, No. 4, 2010, pp. 967-984. http://dx.doi.org/10.1016/j.jmb.2009.12.030
|
[28]
|
P. A. Barker, “High Affinity Not in the Vicinity?” Neuron, Vol. 53, No. 1, 2007, pp. 1-4. http://dx.doi.org/10.1016/j.neuron.2006.12.018
|
[29]
|
G. M. Ross, I. L. Shamovsky, G. Lawrance, M. Solc, S. M. Dostaler, D. F. Weaver and R. J. Riopelle, “Reciprocal Modulation of TrkA and p75NTR Affinity States Is Mediated by Direct Receptor Interactions,” European Journal of Neuroscience, Vol. 10, No. 3, 1998, pp. 890-898. http://dx.doi.org/10.1046/j.1460-9568.1998.00094.x
|